IMMUNIC, INC. - 8-K Filing

Immunic, Inc. reports Q3 2026 results and announces top-line data for Phase 3 ENSURE trials expected in December 2026. (Items: 2.02 Results of Operations and Financial Condition On November 13, 2026, Immunic, Inc, 9.01 Financial Statements and Exhibits Exhibit Description 99)

SEC EDGAR · November 13, 2026, 13:00 UTC

Tickers: $IMUX

Read the full article at SEC EDGAR

Part of the story IMMUNIC, INC. - 8-K Filing (2 articles)

More Regulatory news

Transglobal Management Group, Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 13:11 UTC
REVVITY, INC. - 8-K Filing SEC EDGAR · November 13, 2026, 13:09 UTC
Owlet, Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 13:05 UTC
PAVmed Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 13:05 UTC
Benitec Biopharma Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 13:02 UTC
AUTOLIV INC - 8-K Filing SEC EDGAR · November 13, 2026, 13:00 UTC
Aveanna Healthcare Holdings, Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 13:00 UTC
Edible Garden AG Inc - 8-K Filing SEC EDGAR · November 13, 2026, 13:00 UTC
AIM ImmunoTech Inc. - 4 Filing SEC EDGAR · November 13, 2026, 13:00 UTC
Verrica Pharmaceuticals Inc. - 10-Q Filing SEC EDGAR · November 13, 2026, 12:53 UTC